Amneal Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $6.35B
- P/E (TTM)
- 39.5
- Dividend yield
- –
Earnings
Next report expected Oct 29, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 30, 2026 | Before market open | $796.00M | $0.18 | $0.30 |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | During market hours | $723.00M | $0.19 | $0.27 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 27, 2026 | Before market open | $814.00M | $0.11 | $0.21 |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 30, 2025 | Before market open | $785.00M | $0.01 | $0.17 |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 21, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 2, 2025 | Before market open | $695.00M | $0.04 | $0.21 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 28, 2025 | Before market open | $731.00M | $-0.10 | $0.12 |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 8, 2024 | Before market open | $702.00M | $0.00 | $0.16 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 9, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 3, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 1, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on May 7, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Capital expenditures | 2026 Full Year | $110.00M | – |
| Adjusted EBITDAnon-GAAP | 2026 Full Year | $740.00M to $770.00M | – |
| Adjusted diluted EPSnon-GAAP | 2026 Full Year | $0.95 to $1.05 | – |
| Operating cash flow, excluding discrete itemsnon-GAAP | 2026 Full Year | $375.00M to $425.00M | – |
| Operating cash flowGAAP | 2026 Full Year | $350.00M to $400.00M | – |
| Net revenueGAAP | 2026 Full Year | $3.05B to $3.15B | – |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Amneal Pharmaceuticals filed with the SEC
Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader
Material agreement · Acquisition or disposition completed · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
AMNEAL REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
AMNEAL REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader;
Material agreement · Results of operations · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
AMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
AMNEAL REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
AMNEAL REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Amneal Announces Proposed Refinancing of Existing Credit Agreement,
Other events · EX-99.1 to Form 8-K
AMNEAL REPORTS CERTAIN PRELIMINARY SECOND QUARTER 2025 FINANCIAL RESULTS
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
AMNEAL REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
AMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
AMNEAL REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K/A
AMNEAL REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Amneal Contact Anthony DiMeo VP, Investor Relations [email protected] Metsera Contact Dan Budwick 1AB [email protected]
Regulation FD disclosure · EX-99.1 to Form 8-K
Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to be launched as CREXONT ® (Carbidopa and Levodopa) Extended-Release Capsules
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
AMNEAL REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
AMNEAL REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
AMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Amneal Announces Move to Nasdaq
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
AMNEAL REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
AMNEAL REPORTS CERTAIN PRELIMINARY THIRD QUARTER 2023 FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
AMNEAL REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE
Other events · EX-99.1 to Form 8-K
AMNEAL REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
AMNEAL REPORTS CERTAIN PRELIMINARY FIRST QUARTER 2023 FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
AMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
AMNEAL REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Amneal Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer – Specialty
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K